Emile Foucat

Université Paris Est
Creteil, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

Journal: Virology journal

Published: February 06, 2026

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: September 18, 2024

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

Journal: Nature communications

Published: April 16, 2024

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Journal: The Journal of infectious diseases

Published: March 15, 2024

Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.

Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.

Journal: Journal of clinical immunology

Published: March 29, 2023

Erratum: CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Erratum: CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Journal: iScience

Published: January 02, 2023

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.

Journal: Journal of clinical immunology

Published: December 23, 2022

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 17, 2021

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Journal: iScience

Published: February 08, 2021

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.

Journal: Journal of virology

Published: December 08, 2020

Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.

Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.

Journal: Journal of clinical immunology

Published: April 29, 2020

Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Journal: Nature communications

Published: September 05, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026